Chardan analyst Geulah Livshits raised the firm’s price target on Krystal Biotech (KRYS) to $323 from $220 and keeps a Buy rating on the shares. The firm is updating its model for FY25 financials, the Vyjuvek launch trajectory, and registrational trial progress for four programs, the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline
- Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages
- Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target
- Krystal Biotech price target raised to $371 from $336 at Citi
- Krystal Biotech Earnings Call Highlights Profitable Growth